QURE:NGS-uniQure N.V. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 18.08

Change

+0.14 (+0.78)%

Market Cap

USD 0.17B

Volume

1.18M

Analyst Target

USD 74.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

uniQure NV is engaged in the field of gene therapy platform across three therapeutic focus areas: Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+5.83 (+1.45%)

USD 104.84B
REGN Regeneron Pharmaceuticals Inc

+14.04 (+1.96%)

USD 78.92B
ARGX argenx NV ADR

+3.25 (+0.50%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+2.80 (+1.20%)

USD 30.22B
MRNA Moderna Inc

+4.96 (+11.65%)

USD 16.10B
UTHR United Therapeutics Corporatio..

+6.94 (+1.95%)

USD 15.91B
RPRX Royalty Pharma Plc

+0.29 (+1.13%)

USD 15.05B
SMMT Summit Therapeutics PLC

+0.69 (+3.95%)

USD 13.43B
INCY Incyte Corporation

+1.28 (+1.78%)

USD 13.41B
BMRN Biomarin Pharmaceutical Inc

+0.83 (+1.24%)

USD 12.74B

ETFs Containing QURE

BBC Virtus LifeSci Biotech Cl.. 0.95 % 0.79 %

-0.06 (-0.23%)

USD 8.55M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.38% 37% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.38% 37% F 58% F
Trailing 12 Months  
Capital Gain 165.88% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 165.88% 94% A 95% A
Trailing 5 Years  
Capital Gain -75.07% 48% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.07% 48% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -31.51% 10% F 6% D-
Dividend Return -31.51% 10% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.75% 75% C 49% F
Risk Adjusted Return -81.31% 12% F 7% C-
Market Capitalization 0.17B 79% B- 69% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.64 60% 88%
Price/Book Ratio 15.28 11% 9%
Price / Cash Flow Ratio -5.85 70% 78%
Price/Free Cash Flow Ratio 0.99 16% 53%
Management Effectiveness  
Return on Equity -147.57% 32% 15%
Return on Invested Capital -64.13% 46% 19%
Return on Assets -16.62% 79% 28%
Debt to Equity Ratio 49.00% 35% 42%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector